BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer

Author: Benzinga Newsdesk | October 20, 2025 06:33am

• Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)
• No new safety or tolerability issues identified in pooled analysis of ongoing pivotal Phase 3 study

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer. The findings are being presented in BriaCell's poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21, 2025 in Berlin, Germany. The Phase 3 data shown is for all patients evaluated regardless of treatment assignment (i.e. is blinded).

Posted In: BCTX TSX:BCT